Healthcare is one of the most important aspects of a healthy nation. A healthy society translates to improved economic growth and subsequent business growth. People have taken this advantage to invest in the healthcare sector as a source of livelihood. Foresite Capital is healthcare growth equity firm with interest in providing affordable health system to patients. The company has generated a lot of profit from the initial investment making it a profitable organization in the healthcare sector. Recently, the firm announced that it had acquired the services of Dr. Molly He. He formerly worked for the Illumina as a senior director. His appointment to Foresite Capital has brought a lot of hope due to increased research output in finding clear solutions in the health sector. Dr. Molly He has over 15 years’ experience in pharmaceutical and genomic research and development making him one of the most sought after scientific researchers.
According to the chief executive officer and managing director of Foresite Capital Jim Tananbaum, his appointment brings more life in the next-generation scientific research. Dr. Molly He has a wealth of experience from the portfolios he held earlier thus making him an outstanding kingpin in drug management and development. At Illumina, he was tasked with protein reagent innovation and improvements. A skill he acquired working in the pharmaceutical industry for over ten years. He holds a degree in biochemistry from the University Nankai University and a subsequent Ph.D. in protein biophysics from the University of California.
Jim Tananbaum is a seasoned entrepreneur with over 25 years’ experience in the healthcare sector. His core business in the area of health is to focus on operational, strategic and financial opportunities to invest. Jim Tananbaum has seized the opportunity to open a franchise in healthcare provision that has brought increased revenue. More details can be found on Crunchbase.
Before joining Foresite Capital, Jim Tananbaum co-founded both GelTex Pharmaceuticals and Theravance, Inc. that performed exceptionally well in the Pharmaceuticals field. Due to improved result from the sale of drugs he had bought earlier, GelTex Pharmaceuticals was later sold for $1.6 billion due to its viability and profit generation. Jim Tananbaum graduated from the Yale University with degrees in BS/BSEE. You can visit LinkedIn for more details.
See more: http://www.officialjimtananbaum.com/